Clinical and virological outcomes of entecavir therapy in patients with chronic hepatitis B: A real life experience
Entecavir (ETV) is a nucleoside analogue (NA) that is effective for treatment of chronic hepatitis B (CHB) due to its low resistance rates and potent antiviral effects. We aimed to evaluate the clinical, biochemical and virological response to ETV in patients without a prior use of nucleos(t)ide (NA...
Gespeichert in:
| Veröffentlicht in: | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2019-01, Vol.25 (1), p.12-16 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 16 |
|---|---|
| container_issue | 1 |
| container_start_page | 12 |
| container_title | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy |
| container_volume | 25 |
| creator | Aljumah, Abdulrahman A. Bin Selayem, Nawaf A. Al-Howti, Sultan Y. Dafallah, Mutasim AlGhamdi, Hamdan Mokhtar, Hazem Albekairy, Abdulkareem M. Sanai, Faisal M. |
| description | Entecavir (ETV) is a nucleoside analogue (NA) that is effective for treatment of chronic hepatitis B (CHB) due to its low resistance rates and potent antiviral effects. We aimed to evaluate the clinical, biochemical and virological response to ETV in patients without a prior use of nucleos(t)ide (NA-naïve) vs. those who failed prior NA use (NA-experienced) in the treatment of CHB.
Patients treated between April 2012 and December 2017 were retrospectively studied. A comparison was made between patients treated with ETV in NA-naïve Vs. NA-experienced. Complete virological response (CVR) was defined as achieving undetectable HBV-DNA level, up to 15 IU/ml, partial virological response (PVR) as 15–200 IU/ml and >200 IU/ml for no virological response (NVR) after one year of therapy.
Overall, 148 patients were included (69 NA-naïve and 79 NA-experienced). In NA-naïve group, 51%, 17% and 32% achieved CVR, PVR and NVR vs. 17%, 9% and 75% in NA-experienced group, respectively (p |
| doi_str_mv | 10.1016/j.jiac.2018.09.014 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2126916926</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1341321X18303544</els_id><sourcerecordid>2126916926</sourcerecordid><originalsourceid>FETCH-LOGICAL-c424t-c08dbaa90afcf4a5e11a78105af818c0b1819777dab15f38a10a88c6180701d83</originalsourceid><addsrcrecordid>eNp9kMuO1DAQRS0EYl78AAvkJZtkqpJ07CA2M615II3EBqTZWdVOhXYrHQfbPY-_xz09sGTlR917pDpCfEQoEbA935QbR7asAHUJXQnYvBHH2NSqUErD23yvGyzqCu-PxEmMGwBUC63fi6Ma6rbVLR6LuBzd5CyNkqZePrjgR__r5e13yfotR-kHyVNiS3kq05oDzc_STXKm5PIgykeX1tKug88gueb9f3JRXn6RFzJwRo1uYMlPM4dcsHwm3g00Rv7wep6Kn9dXP5a3xd33m2_Li7vCNlWTCgu6XxF1QIMdGlowIimNsKBBo7awQo2dUqqnFS6GWhMCaW1b1KAAe12fis8H7hz87x3HZLYuWh5Hmtjvoqmwajtsu6rN0eoQtcHHGHgwc3BbCs8Gwexlm43ZyzZ72QY6k2Xn0qdX_m615f5f5a_dHPh6CHDe8sFxMNG-GOhdYJtM793_-H8AwBWRgQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2126916926</pqid></control><display><type>article</type><title>Clinical and virological outcomes of entecavir therapy in patients with chronic hepatitis B: A real life experience</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Aljumah, Abdulrahman A. ; Bin Selayem, Nawaf A. ; Al-Howti, Sultan Y. ; Dafallah, Mutasim ; AlGhamdi, Hamdan ; Mokhtar, Hazem ; Albekairy, Abdulkareem M. ; Sanai, Faisal M.</creator><creatorcontrib>Aljumah, Abdulrahman A. ; Bin Selayem, Nawaf A. ; Al-Howti, Sultan Y. ; Dafallah, Mutasim ; AlGhamdi, Hamdan ; Mokhtar, Hazem ; Albekairy, Abdulkareem M. ; Sanai, Faisal M.</creatorcontrib><description>Entecavir (ETV) is a nucleoside analogue (NA) that is effective for treatment of chronic hepatitis B (CHB) due to its low resistance rates and potent antiviral effects. We aimed to evaluate the clinical, biochemical and virological response to ETV in patients without a prior use of nucleos(t)ide (NA-naïve) vs. those who failed prior NA use (NA-experienced) in the treatment of CHB.
Patients treated between April 2012 and December 2017 were retrospectively studied. A comparison was made between patients treated with ETV in NA-naïve Vs. NA-experienced. Complete virological response (CVR) was defined as achieving undetectable HBV-DNA level, up to 15 IU/ml, partial virological response (PVR) as 15–200 IU/ml and >200 IU/ml for no virological response (NVR) after one year of therapy.
Overall, 148 patients were included (69 NA-naïve and 79 NA-experienced). In NA-naïve group, 51%, 17% and 32% achieved CVR, PVR and NVR vs. 17%, 9% and 75% in NA-experienced group, respectively (p < 0.001). HBsAg seroconversion was achieved in 5.8% in NA-naïve group vs. 6.3% in NA-experienced group (p = 1.00). HBeAg seroconversion was 17% in NA-naïve group and 25% in NA-experienced group (p = 0.24). There was no significant difference in alanine transaminase normalization or in mortality rate between both groups; p = 0.87 and p = 1.00 respectively.
ETV therapy in CHB results in a better virological response in NA-naïve patients compared to NA-experienced. There were no differences between both groups in regards to the rate of HBsAg or HBeAg seroconversions, biochemical improvements or mortality.</description><identifier>ISSN: 1341-321X</identifier><identifier>EISSN: 1437-7780</identifier><identifier>DOI: 10.1016/j.jiac.2018.09.014</identifier><identifier>PMID: 30366861</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adefovir ; Adult ; Aged ; Alanine Transaminase - blood ; Antiviral Agents - pharmacology ; Antiviral Agents - therapeutic use ; DNA, Viral - blood ; Entecavir ; Female ; Guanine - analogs & derivatives ; Guanine - pharmacology ; Guanine - therapeutic use ; HBV ; Hepatitis B e Antigens - blood ; Hepatitis B e Antigens - immunology ; Hepatitis B Surface Antigens - blood ; Hepatitis B Surface Antigens - immunology ; Hepatitis B virus - drug effects ; Hepatitis B virus - immunology ; Hepatitis B, Chronic - blood ; Hepatitis B, Chronic - drug therapy ; Hepatitis B, Chronic - mortality ; Humans ; Male ; Middle Aged ; Nucleoside analogue ; Retrospective Studies ; Seroconversion</subject><ispartof>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2019-01, Vol.25 (1), p.12-16</ispartof><rights>2018 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases</rights><rights>Copyright © 2018 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c424t-c08dbaa90afcf4a5e11a78105af818c0b1819777dab15f38a10a88c6180701d83</citedby><cites>FETCH-LOGICAL-c424t-c08dbaa90afcf4a5e11a78105af818c0b1819777dab15f38a10a88c6180701d83</cites><orcidid>0000-0002-6156-4921</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30366861$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aljumah, Abdulrahman A.</creatorcontrib><creatorcontrib>Bin Selayem, Nawaf A.</creatorcontrib><creatorcontrib>Al-Howti, Sultan Y.</creatorcontrib><creatorcontrib>Dafallah, Mutasim</creatorcontrib><creatorcontrib>AlGhamdi, Hamdan</creatorcontrib><creatorcontrib>Mokhtar, Hazem</creatorcontrib><creatorcontrib>Albekairy, Abdulkareem M.</creatorcontrib><creatorcontrib>Sanai, Faisal M.</creatorcontrib><title>Clinical and virological outcomes of entecavir therapy in patients with chronic hepatitis B: A real life experience</title><title>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</title><addtitle>J Infect Chemother</addtitle><description>Entecavir (ETV) is a nucleoside analogue (NA) that is effective for treatment of chronic hepatitis B (CHB) due to its low resistance rates and potent antiviral effects. We aimed to evaluate the clinical, biochemical and virological response to ETV in patients without a prior use of nucleos(t)ide (NA-naïve) vs. those who failed prior NA use (NA-experienced) in the treatment of CHB.
Patients treated between April 2012 and December 2017 were retrospectively studied. A comparison was made between patients treated with ETV in NA-naïve Vs. NA-experienced. Complete virological response (CVR) was defined as achieving undetectable HBV-DNA level, up to 15 IU/ml, partial virological response (PVR) as 15–200 IU/ml and >200 IU/ml for no virological response (NVR) after one year of therapy.
Overall, 148 patients were included (69 NA-naïve and 79 NA-experienced). In NA-naïve group, 51%, 17% and 32% achieved CVR, PVR and NVR vs. 17%, 9% and 75% in NA-experienced group, respectively (p < 0.001). HBsAg seroconversion was achieved in 5.8% in NA-naïve group vs. 6.3% in NA-experienced group (p = 1.00). HBeAg seroconversion was 17% in NA-naïve group and 25% in NA-experienced group (p = 0.24). There was no significant difference in alanine transaminase normalization or in mortality rate between both groups; p = 0.87 and p = 1.00 respectively.
ETV therapy in CHB results in a better virological response in NA-naïve patients compared to NA-experienced. There were no differences between both groups in regards to the rate of HBsAg or HBeAg seroconversions, biochemical improvements or mortality.</description><subject>Adefovir</subject><subject>Adult</subject><subject>Aged</subject><subject>Alanine Transaminase - blood</subject><subject>Antiviral Agents - pharmacology</subject><subject>Antiviral Agents - therapeutic use</subject><subject>DNA, Viral - blood</subject><subject>Entecavir</subject><subject>Female</subject><subject>Guanine - analogs & derivatives</subject><subject>Guanine - pharmacology</subject><subject>Guanine - therapeutic use</subject><subject>HBV</subject><subject>Hepatitis B e Antigens - blood</subject><subject>Hepatitis B e Antigens - immunology</subject><subject>Hepatitis B Surface Antigens - blood</subject><subject>Hepatitis B Surface Antigens - immunology</subject><subject>Hepatitis B virus - drug effects</subject><subject>Hepatitis B virus - immunology</subject><subject>Hepatitis B, Chronic - blood</subject><subject>Hepatitis B, Chronic - drug therapy</subject><subject>Hepatitis B, Chronic - mortality</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nucleoside analogue</subject><subject>Retrospective Studies</subject><subject>Seroconversion</subject><issn>1341-321X</issn><issn>1437-7780</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMuO1DAQRS0EYl78AAvkJZtkqpJ07CA2M615II3EBqTZWdVOhXYrHQfbPY-_xz09sGTlR917pDpCfEQoEbA935QbR7asAHUJXQnYvBHH2NSqUErD23yvGyzqCu-PxEmMGwBUC63fi6Ma6rbVLR6LuBzd5CyNkqZePrjgR__r5e13yfotR-kHyVNiS3kq05oDzc_STXKm5PIgykeX1tKug88gueb9f3JRXn6RFzJwRo1uYMlPM4dcsHwm3g00Rv7wep6Kn9dXP5a3xd33m2_Li7vCNlWTCgu6XxF1QIMdGlowIimNsKBBo7awQo2dUqqnFS6GWhMCaW1b1KAAe12fis8H7hz87x3HZLYuWh5Hmtjvoqmwajtsu6rN0eoQtcHHGHgwc3BbCs8Gwexlm43ZyzZ72QY6k2Xn0qdX_m615f5f5a_dHPh6CHDe8sFxMNG-GOhdYJtM793_-H8AwBWRgQ</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Aljumah, Abdulrahman A.</creator><creator>Bin Selayem, Nawaf A.</creator><creator>Al-Howti, Sultan Y.</creator><creator>Dafallah, Mutasim</creator><creator>AlGhamdi, Hamdan</creator><creator>Mokhtar, Hazem</creator><creator>Albekairy, Abdulkareem M.</creator><creator>Sanai, Faisal M.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6156-4921</orcidid></search><sort><creationdate>20190101</creationdate><title>Clinical and virological outcomes of entecavir therapy in patients with chronic hepatitis B: A real life experience</title><author>Aljumah, Abdulrahman A. ; Bin Selayem, Nawaf A. ; Al-Howti, Sultan Y. ; Dafallah, Mutasim ; AlGhamdi, Hamdan ; Mokhtar, Hazem ; Albekairy, Abdulkareem M. ; Sanai, Faisal M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c424t-c08dbaa90afcf4a5e11a78105af818c0b1819777dab15f38a10a88c6180701d83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adefovir</topic><topic>Adult</topic><topic>Aged</topic><topic>Alanine Transaminase - blood</topic><topic>Antiviral Agents - pharmacology</topic><topic>Antiviral Agents - therapeutic use</topic><topic>DNA, Viral - blood</topic><topic>Entecavir</topic><topic>Female</topic><topic>Guanine - analogs & derivatives</topic><topic>Guanine - pharmacology</topic><topic>Guanine - therapeutic use</topic><topic>HBV</topic><topic>Hepatitis B e Antigens - blood</topic><topic>Hepatitis B e Antigens - immunology</topic><topic>Hepatitis B Surface Antigens - blood</topic><topic>Hepatitis B Surface Antigens - immunology</topic><topic>Hepatitis B virus - drug effects</topic><topic>Hepatitis B virus - immunology</topic><topic>Hepatitis B, Chronic - blood</topic><topic>Hepatitis B, Chronic - drug therapy</topic><topic>Hepatitis B, Chronic - mortality</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nucleoside analogue</topic><topic>Retrospective Studies</topic><topic>Seroconversion</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aljumah, Abdulrahman A.</creatorcontrib><creatorcontrib>Bin Selayem, Nawaf A.</creatorcontrib><creatorcontrib>Al-Howti, Sultan Y.</creatorcontrib><creatorcontrib>Dafallah, Mutasim</creatorcontrib><creatorcontrib>AlGhamdi, Hamdan</creatorcontrib><creatorcontrib>Mokhtar, Hazem</creatorcontrib><creatorcontrib>Albekairy, Abdulkareem M.</creatorcontrib><creatorcontrib>Sanai, Faisal M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aljumah, Abdulrahman A.</au><au>Bin Selayem, Nawaf A.</au><au>Al-Howti, Sultan Y.</au><au>Dafallah, Mutasim</au><au>AlGhamdi, Hamdan</au><au>Mokhtar, Hazem</au><au>Albekairy, Abdulkareem M.</au><au>Sanai, Faisal M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical and virological outcomes of entecavir therapy in patients with chronic hepatitis B: A real life experience</atitle><jtitle>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</jtitle><addtitle>J Infect Chemother</addtitle><date>2019-01-01</date><risdate>2019</risdate><volume>25</volume><issue>1</issue><spage>12</spage><epage>16</epage><pages>12-16</pages><issn>1341-321X</issn><eissn>1437-7780</eissn><abstract>Entecavir (ETV) is a nucleoside analogue (NA) that is effective for treatment of chronic hepatitis B (CHB) due to its low resistance rates and potent antiviral effects. We aimed to evaluate the clinical, biochemical and virological response to ETV in patients without a prior use of nucleos(t)ide (NA-naïve) vs. those who failed prior NA use (NA-experienced) in the treatment of CHB.
Patients treated between April 2012 and December 2017 were retrospectively studied. A comparison was made between patients treated with ETV in NA-naïve Vs. NA-experienced. Complete virological response (CVR) was defined as achieving undetectable HBV-DNA level, up to 15 IU/ml, partial virological response (PVR) as 15–200 IU/ml and >200 IU/ml for no virological response (NVR) after one year of therapy.
Overall, 148 patients were included (69 NA-naïve and 79 NA-experienced). In NA-naïve group, 51%, 17% and 32% achieved CVR, PVR and NVR vs. 17%, 9% and 75% in NA-experienced group, respectively (p < 0.001). HBsAg seroconversion was achieved in 5.8% in NA-naïve group vs. 6.3% in NA-experienced group (p = 1.00). HBeAg seroconversion was 17% in NA-naïve group and 25% in NA-experienced group (p = 0.24). There was no significant difference in alanine transaminase normalization or in mortality rate between both groups; p = 0.87 and p = 1.00 respectively.
ETV therapy in CHB results in a better virological response in NA-naïve patients compared to NA-experienced. There were no differences between both groups in regards to the rate of HBsAg or HBeAg seroconversions, biochemical improvements or mortality.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>30366861</pmid><doi>10.1016/j.jiac.2018.09.014</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-6156-4921</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1341-321X |
| ispartof | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2019-01, Vol.25 (1), p.12-16 |
| issn | 1341-321X 1437-7780 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2126916926 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adefovir Adult Aged Alanine Transaminase - blood Antiviral Agents - pharmacology Antiviral Agents - therapeutic use DNA, Viral - blood Entecavir Female Guanine - analogs & derivatives Guanine - pharmacology Guanine - therapeutic use HBV Hepatitis B e Antigens - blood Hepatitis B e Antigens - immunology Hepatitis B Surface Antigens - blood Hepatitis B Surface Antigens - immunology Hepatitis B virus - drug effects Hepatitis B virus - immunology Hepatitis B, Chronic - blood Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - mortality Humans Male Middle Aged Nucleoside analogue Retrospective Studies Seroconversion |
| title | Clinical and virological outcomes of entecavir therapy in patients with chronic hepatitis B: A real life experience |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T01%3A58%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20and%20virological%20outcomes%20of%20entecavir%20therapy%20in%20patients%20with%20chronic%20hepatitis%20B:%20A%20real%20life%20experience&rft.jtitle=Journal%20of%20infection%20and%20chemotherapy%20:%20official%20journal%20of%20the%20Japan%20Society%20of%20Chemotherapy&rft.au=Aljumah,%20Abdulrahman%20A.&rft.date=2019-01-01&rft.volume=25&rft.issue=1&rft.spage=12&rft.epage=16&rft.pages=12-16&rft.issn=1341-321X&rft.eissn=1437-7780&rft_id=info:doi/10.1016/j.jiac.2018.09.014&rft_dat=%3Cproquest_cross%3E2126916926%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2126916926&rft_id=info:pmid/30366861&rft_els_id=S1341321X18303544&rfr_iscdi=true |